secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001528287-22-000017
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace Q2 revenue $10.2M (-19% YoY); net loss $12.7M; signs exclusive DIXI Medical SEEG distribution deal
--------------------------------------------------------------------------------

- Q2 total revenue $10.2M vs $12.6M YoY; initial implant revenue $8.0M, replacement $2.2M.
- Net loss $12.7M vs $8.5M YoY; operating expenses $18.4M up from $14.0M.
- FY 2022 guidance: total revenue $43-45M, initial implant $34-36M; DIXI Medical revenue ~$1.5M in Q4.
- Signed exclusive 3-year U.S. distribution deal for DIXI Medical SEEG electrodes; total payments of $4.5M.
- Cash and equivalents $92.4M, down from $103.2M at March 31; long-term borrowings $51.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000152828722000017/0001528287-22-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000152828722000017/npce-20220811.htm
  HTML page:      https://secwatch.observer/filing/0001528287-22-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer